SEC Form 3 · accession 0001447348-15-000022
PROGENICS PHARMACEUTICALS INC · PGNX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Vivien Wong
Officer — Executive Vice President
Period of report
Apr 1, 2015
Accepted (ET)
Apr 1, 2015 · 9:22 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000835887
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 4,121 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F1 | $4.70 | holding | — | — | — | — | Mar 3, 2024 | Common Stock | 127,800 | — | D |
| Non-Qualified Stock Option (right to buy)F2 | $4.83 | holding | — | — | — | — | Nov 1, 2020 | Common Stock | 25,000 | — | D |
| Non-Qualified Stock Option (right to buy)F2 | $5.03 | holding | — | — | — | — | Apr 4, 2023 | Common Stock | 48,000 | — | D |
| Non-Qualified Stock Option (right to buy)F2 | $5.33 | holding | — | — | — | — | Jul 1, 2019 | Common Stock | 3,375 | — | D |
| Non-Qualified Stock Option (right to buy)F2 | $5.35 | holding | — | — | — | — | Jul 1, 2020 | Common Stock | 6,000 | — | D |
| Non-Qualified Stock Option (right to buy)F2 | $6.65 | holding | — | — | — | — | Mar 2, 2025 | Common Stock | 66,000 | — | D |
| Non-Qualified Stock Option (right to buy)F2 | $7.40 | holding | — | — | — | — | Jul 1, 2021 | Common Stock | 60,000 | — | D |
| Non-Qualified Stock Option (right to buy)F2 | $9.81 | holding | — | — | — | — | Mar 1, 2022 | Common Stock | 40,000 | — | D |
| Non-Qualified Stock Option (right to buy)F2 | $16.05 | holding | — | — | — | — | Jul 1, 2018 | Common Stock | 2,589 | — | D |
| Non-Qualified Stock Option (right to buy)F3 | $22.67 | holding | — | — | — | — | Nov 1, 2017 | Common Stock | 6,000 | — | D |
Explanation of responses
- F1Amount consists of 2 separate grants. 75,000 stock options become exercisable in four equal annual installments and 52,800 become exercisable in three equal annual installments both commencing one year from grant date.
- F2The stock options become exercisable in three equal annual installments, commencing one year from the grant date.
- F3The stock options become exercisable in five equal installments, commencing one year from the grant date.